, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy.

Eley JG, Friedrich T, Homann KL, Howell RM, Scholz M, Durante M, Newhauser WD
Int J Radiat Oncol Biol Phys. 2016 95 (1): 279-286

PMID: 27084647 · PMCID: PMC4844193 · DOI:10.1016/j.ijrobp.2016.02.032

PURPOSE - This work proposes a theoretical framework that enables comparative risk predictions for second cancer incidence after particle beam therapy for different ion species for individual patients, accounting for differences in relative biological effectiveness (RBE) for the competing processes of tumor initiation and cell inactivation. Our working hypothesis was that use of carbon-ion therapy instead of proton therapy would show a difference in the predicted risk of second cancer incidence in the breast for a sample of Hodgkin lymphoma (HL) patients.

METHODS AND MATERIALS - We generated biologic treatment plans and calculated relative predicted risks of second cancer in the breast by using two proposed methods: a full model derived from the linear quadratic model and a simpler linear-no-threshold model.

RESULTS - For our reference calculation, we found the predicted risk of breast cancer incidence for carbon-ion plans-to-proton plan ratio, , to be 0.75 ± 0.07 but not significantly smaller than 1 (P=.180).

CONCLUSIONS - Our findings suggest that second cancer risks are, on average, comparable between proton therapy and carbon-ion therapy.

Copyright © 2016 Elsevier Inc. All rights reserved.

MeSH Terms (23)

Breast Breast Neoplasms Carbon Esophagus Female Heart Heavy Ion Radiotherapy Hodgkin Disease Humans Incidence Linear Models Lung Neoplasms, Second Primary Organs at Risk Proton Therapy Radiography Radiotherapy Dosage Radiotherapy Planning, Computer-Assisted Relative Biological Effectiveness Risk Assessment Sensitivity and Specificity Spinal Cord Uncertainty

Connections (1)

This publication is referenced by other Labnodes entities: